Safety and immunogenicity of Ad26.COV2.S in adolescents: Phase 2 randomized clinical trial

Safety and immunogenicity of Ad26.COV2.S in adolescents: Phase 2 randomized clinical trial

We conducted a randomized, Phase 2 trial to assess the safety and humoral immunogenicity of reduced doses/dose volume of the standard dose of Ad26.COV2.S COVID-19 vaccine (5 × 1010 viral particles [vp]) in healthy adolescents aged 12–17 years. Participants were randomly assigned to receive Ad26.COV2...

Full description

Saved in:
Bibliographic Details
Main Authors: Jelena Tica, Veronica V. Rezelj, Benoit Baron, Vitalija van Paassen, Javier Zaidman, Lee Fairlie, Gert Scheper, Mathieu Le Gars, Frank Struyf, Macaya Douoguih, Javier Ruiz-Guiñazú
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
Ad26.COV2.S
COVID-19 vaccine
adolescent
immunogenicity
safety
virus vector vaccine
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2025.2450120
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/21645515.2025.2450120

Similar Items